Radioembolization for hepatocellular carcinoma: what clinicians need to know
- Author:
Jin Woo CHOI
1
;
Hyo-Cheol KIM
Author Information
- Publication Type:Review Article
- From:Journal of Liver Cancer 2022;22(1):4-13
- CountryRepublic of Korea
- Language:English
- Abstract: Transarterial radioembolization (TARE) with yttrium 90 (90Y) has been used in the management of hepatocellular carcinoma (HCC) for more than 10 years in Korea. There are two types of 90Y radioactive microspheres available, namely, glass and resin microspheres, with comparable clinical outcomes. In general, TARE outperforms transarterial chemoembolization regarding post-embolization syndrome, time to progression, tumor downsizing for liver transplantation, and hospitalization stay. Although TARE is commonly recommended for patients with unresectable large HCCs, it can be an alternative to or performed in combination with ablation, surgical resection, and systemic treatment. This review aimed to address 90Y radioactive microspheres, patient selection, clinical outcomes, simulation tests, radioembolization procedures, follow-up imaging, and complications.
